T‐cell receptor sequencing demonstrates persistence of virus‐specific T cells after antiviral immunotherapy

Viral infections are a serious cause of morbidity and mortality following haematopoietic stem cell transplantation (HSCT). Adoptive cellular therapy with virus‐specific T cells (VSTs) has been successful in preventing or treating targeted viruses in prior studies, but the composition of ex vivo expanded VST and the critical cell populations that mediate antiviral activity in vivo are not well defined. We utilized deep sequencing of the T‐cell receptor beta chain (TCRB) in order to classify and track VST populations in 12 patients who received VSTs following HSCT to prevent or treat viral infections. TCRB sequencing was performed on sorted VST products and patient peripheral blood mononuclear cells samples. TCRB diversity was gauged using the Shannon entropy index, and repertoire similarity determined using the Morisita–Horn index. Similarity indices reflected an early change in TCRB diversity in eight patients, and TCRB clonotypes corresponding to targeted viral epitopes expanded in eight patients. TCRB repertoire diversity increased in nine patients, and correlated with cytomegalovirus (CMV) viral load following VST infusion (P = 0·0071). These findings demonstrate that allogeneic VSTs can be tracked via TCRB sequencing, and suggests that T‐cell receptor repertoire diversity may be critical for the control of CMV reactivation after HSCT.

[1]  L. Notarangelo,et al.  Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. , 2017, Blood.

[2]  Andrew K. Sewell,et al.  VDJdb: a curated database of T-cell receptor sequences with known antigen specificity , 2017, Nucleic Acids Res..

[3]  R. Krance,et al.  Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Alessandro Sette,et al.  Identifying specificity groups in the T cell receptor repertoire , 2017, Nature.

[5]  Thomas M. Schmitt,et al.  Tracking the fate and origin of clinically relevant adoptively transferred CD8+ T cells in vivo , 2017, Science Immunology.

[6]  R. Chemaly,et al.  How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. , 2016, Blood.

[7]  C. Picard,et al.  Specific T cells for the treatment of cytomegalovirus and/or adenovirus in the context of hematopoietic stem cell transplantation. , 2016, The Journal of allergy and clinical immunology.

[8]  H. Heslop,et al.  T cells for viral infections after allogeneic hematopoietic stem cell transplant. , 2016, Blood.

[9]  Pierre Lechat,et al.  Public T cell receptors confer high-avidity CD4 responses to HIV controllers. , 2016, The Journal of clinical investigation.

[10]  G. Lucchini,et al.  Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. , 2016, The Journal of allergy and clinical immunology.

[11]  R. O'reilly,et al.  Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections , 2016, Bone Marrow Transplantation.

[12]  V. Buchholz,et al.  Role of memory T cell subsets for adoptive immunotherapy. , 2016, Seminars in immunology.

[13]  R. O'reilly,et al.  Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  Bruce R. Blazar,et al.  CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire. , 2015, Blood.

[15]  J. Rodgers,et al.  CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo , 2015, Science Translational Medicine.

[16]  Malcolm K. Brenner,et al.  Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCT , 2014, Science Translational Medicine.

[17]  D. Douek,et al.  PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. , 2014, The Journal of clinical investigation.

[18]  Sam Darko,et al.  Human syndromes of immunodeficiency and dysregulation are characterized by distinct defects in T-cell receptor repertoire development. , 2014, The Journal of allergy and clinical immunology.

[19]  P. Hanley,et al.  The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care , 2014, Cytotherapy.

[20]  Grzegorz A Rempala,et al.  Methods for diversity and overlap analysis in T-cell receptor populations , 2012, Journal of Mathematical Biology.

[21]  U. Gerdemann,et al.  Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  M. Faham,et al.  Combining Next-Generation Sequencing and Immune Assays: A Novel Method for Identification of Antigen-Specific T Cells , 2013, PloS one.

[23]  J. Jensen,et al.  Rapid Intrahost Evolution of Human Cytomegalovirus Is Shaped by Demography and Positive Selection , 2013, PLoS genetics.

[24]  S. Pai,et al.  Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. , 2013, Blood.

[25]  K. Byth,et al.  Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. , 2013, Blood.

[26]  P. Ljungman,et al.  Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  U. Gerdemann,et al.  Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections , 2012, Molecular Therapy.

[28]  Todd M. Allen,et al.  TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection , 2012, Nature Immunology.

[29]  J. Teruya-Feldstein,et al.  Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. , 2012, Blood.

[30]  K. Peggs,et al.  Management of multidrug‐resistant viruses in the immunocompromised host , 2012, British journal of haematology.

[31]  Brigitte Autran,et al.  Escape from highly effective public CD8+ T-cell clonotypes by HIV. , 2011, Blood.

[32]  Hao Liu,et al.  Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. , 2010, Blood.

[33]  P. Hanley,et al.  Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. , 2009, Blood.

[34]  M. Boeckh,et al.  How we treat cytomegalovirus in hematopoietic cell transplant recipients. , 2009, Blood.

[35]  Chung-Che Chang,et al.  Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals , 2006, Nature Medicine.

[36]  M. Bonneville,et al.  Selection of T Cell Clones Expressing High-Affinity Public TCRs within Human Cytomegalovirus-Specific CD8 T Cell Responses1 , 2005, The Journal of Immunology.

[37]  Anne E Magurran,et al.  Biological diversity , 2005, Current Biology.

[38]  Mitchell R. Smith Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance , 2003, Oncogene.

[39]  M. Bonneville,et al.  Frequent Contribution of T Cell Clonotypes with Public TCR Features to the Chronic Response Against a Dominant EBV-Derived Epitope: Application to Direct Detection of Their Molecular Imprint on the Human Peripheral T Cell Repertoire1 , 2000, The Journal of Immunology.

[40]  J. Cohen Primary Immunodeficiencies Associated with EBV Disease. , 2015, Current topics in microbiology and immunology.

[41]  S. Mackinnon,et al.  Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  M. Wainberg,et al.  Replication of cytomegalovirus in human thymic epithelial cells , 2004, Medical Microbiology and Immunology.

[43]  N. W. PIRIE,et al.  Biological Diversity , 1964 .